An inducible RIPK3-driven necroptotic system enhances cancer cell-based immunotherapy and ensures safety.

Autor: Chen KS; Center for Stem Cell and Translational Immunotherapy, Brigham and Women's Hospital, Harvard Medical School, Boston, United States of America., Manoury-Battais S; Center for Stem Cell and Translational Immunotherapy, Brigham and Women's Hospital, Harvard Medical School, Boston, United States of America., Kanaya N; Center for Stem Cell and Translational Immunotherapy, Brigham and Women's Hospital, Harvard Medical School, Boston, United States of America., Vogiatzi I; Center for Stem Cell and Translational Immunotherapy, Brigham and Women's Hospital, Harvard Medical School, Boston, United States of America., Borges P; Center for Stem Cell and Translational Immunotherapy, Brigham and Women's Hospital, Harvard Medical School, Boston, United States of America., Kruize SJ; Center for Stem Cell and Translational Immunotherapy, Brigham and Women's Hospital, Harvard Medical School, Boston, United States of America., Chen YC; Center for Stem Cell and Translational Immunotherapy, Brigham and Women's Hospital, Harvard Medical School, Boston, United States of America., Lin LY; Center for Stem Cell and Translational Immunotherapy, Brigham and Women's Hospital, Harvard Medical School, Boston, United States of America., Rossignoli F; Center for Stem Cell and Translational Immunotherapy, Brigham and Women's Hospital, Harvard Medical School, Boston, United States of America., Mendonca NC; Center for Stem Cell and Translational Immunotherapy, Brigham and Women's Hospital, Harvard Medical School, Boston, United States of America., Shah K; Center for Stem Cell and Translational Immunotherapy, Brigham and Women's Hospital, Harvard Medical School, Boston, United States of America.

Publikováno v: The Journal of clinical investigation [J Clin Invest] 2024 Nov 19. Date of Electronic Publication: 2024 Nov 19.